Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01895842
Title Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center|Incyte Corporation
Indications

bone marrow cancer

Therapies

Ruxolitinib

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST